Kanker-actueel Everolimus (Afinitor) with exemestane provides significantly longer disease-free time for women with hormone sensitive breast cancer, even where there was resistance to Arimidex and Femara

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

Arimidex - anastrozole information and study overview

Breast Cancer: Exemestane Exemestane = gives much better effect on overall survival and disease-free and reduced risk of recurrence than tamoxifen so large phase III study. Article updated March 28, 2011

Breast Cancer: Exemestane Exemestane = drug approved by FDA as a treatment for women with breast cancer at the age of the transfer.

Femara: Information on proven effectiveness and use of Femara - Letrozole in breast cancer put together.

Breast cancer: Femara - gives letrozole in women with breast cancer five years tamoxifen who have used a significantly longer disease-free time but not significantly better overall survival compared to placebo.

Hormones: Injections of goserelin - Zoladex given alongside chemotherapy in women with breast cancer who are menstruating completely protect ovaries. Freezing seems better alternative. Article updated August 3, 2011

Hormones: Women who take hormone treatments to counter disadvantages of transition have significantly higher risk of breast cancer and more serious nature of breast cancer, said major long-term study of WHI - Women's Health Initiative

Breast cancer: Hormones in breast cancer: Hormone therapy and during the transition caused 54-93% chance galwegziekte so randomized study of more than 14,000 healthy women.

Hormone therapy: After two to three years to switch from tamoxifen to Arimidex provides significantly less risk of a recurrence of breast cancer, two large randomized trials with a duration of three years.

Hormones: Breast cancer patients who survive hormone treatments / aromaseremmers such as Letrazole - Femara and Arimidex - Anastrazole or survive with the help of chemotherapy experienced still greater risk of osteoporosis = osteoporosis in later life. Tamoxifen causes less osteoporosis later in life than the newer hormone treatments / aromaseremmers which in turn is significantly better effect on the breast itself. Read study abstract explanatory article, osteoporosis and breast cancer in alphabetical list. Article updated August 3, 2011

BRCA1 and BCRA2: Prophylactic mastectomy (preventive surgery of breasts) and salpingo-oophorectomy (removal of ovaries, fallopian tubes plus) in women with BRCA1 and BRCA2 mutation works great at preventing breast cancer and ovarian cancer. Shows a large long-term study of 2500 women and BCRA1 BCRA2 mutation. Article posted September 2, 2010

Red clover isoflavones are not significantly improved bone density on mammography than placebo, significantly better than conventional hormone therapy for women with breast cancer so randomized phase III study. Article updated March 28, 2011

Tamoxifen: Tamoxifen use in breast cancer patients in addition to the antidepressant paroxetine are more likely to die prematurely. This shows a 12 year population in Canada in 2430 women over 66 years with breast cancer. Article posted February 10, 2010

Tamoxifen and radiotherapy: Tackling breast cancer with tamoxifen after surgery and radiation in women over 70 years seems pointless. For women aged 50 years, this approach is sensible for local metastases, although again no difference in getting remote metastasis and survival between the two groups, according to recently published randomized trials. Article updated March 28, 2011.

Tamoxifen: Surgery in older women with breast cancer followed by tamoxifen provides no difference in survival than tamoxifen alone, says five-year randomized study in 476 women. Article updated July 12, 2011

Tamoxifen: Tamoxifen information put together.

Aromasin - Exemestane produces slightly better results in postmenopausal women with breast cancer than Arimidex - Anastrazole but not significantly. Or offers to switch from Arimidex to Aromasin if that fails to catch on more opportunities than the other way. Article posted August 3, 2011

Everolimus (Afinitor) with exemestane provides significantly longer disease-free time for women with hormone sensitive breast cancer, even where there was resistance to Arimidex and Femara. Article posted September 27, 2011

Everolimus (Afinitor) with exemestane provides significantly longer disease-free time for women with hormone sensitive breast cancer, even where there was resistance to Arimidex and Femara. Article posted September 27, 2011

September 27, 2011: Source: Medscape

Women with hormone-sensitive breast cancer, but resistance to Arimidex and / or Femara now seem still to have another option. Everolimus given alongside fulvestrand - Exemestane appears particularly well to save. From a randomized phase III study shows that the disease-free time was prolonged from 2.8 months to 6.9 months compared with exemestane in women only where the treatment would be successful. The response for the combination treatment went from 0.4% to 9.6%. This does not seem much but if 1 in 10 women who appeared still uitbehandeld an effective approach to get that is still good. Moreover, even though everolimus in advanced kidney cancer , where other means failed, and in Waldenstrom proven to be an excellent resource. Here is an excerpt from an article by Medscape on the recent study presented at the EMCC yesterday.

The combination of everolimus (Afinitor, Novartis) plus exemestane HAS produced "the strongest data ever seen in estrogen receptor-positive breast cancer 699528693

Source: Medscape

The results from this large phase 3 trial show that "Everolimus is the first agent to Enhance Hormone therapy in refractory ER-positive breast cancer patients," and They represent a "paradigm shift in the management or thesis patient," he told delegates.

The study was conducted BOLERO-2 in 724 postmenopausal women with ER-positive but HER2-negative advanced breast cancer who had bone Previously Treated with and had become refractory to the nonsteroidal aromatase inhibitor letrozole and anastrozole. Previous therapies included tamoxifen (in 48% patients), fulvestrant (16%) and chemotherapy (in 68%).

"When responding to Stop patiënten Hormonal therapy, the benefits from any secondary therapy are limited," Dr.. Baselga Explained.

All of the women in the study received exemestane, a steroidal aromatase inhibitor which is a Slightly different profile than with letrozole or anastrozole. In Addition, women were randomized in a 2:1 ratio to receive everolimus (10 mg / day orally).

A preplanned interim analysis found significantly improved everolimus That progression-free survival, the primary end point of the study. Median progression-free survival, reassessed by local investigators, was longer with exemestane than with everolimus plus exemestane alone (6.9 vs. 2.8 months, hazard ratio [HR], 0.43, P ≤ .0001). These figures Slightly changed after central assessment (10.6 vs. 4.1 months, HR 0.36, P <.0001).

These results were highly significant, Dr.. Baselga emphasized. "This is a very uncommon result in meta-static disease," he said at a press briefing. "Very Seldom do you see Such an effect."

In Addition, there was a significantly Greater response rates (9.5% vs 0.4%) and clinical benefit (33.4% vs. 18.0%) in the combination group. Dr. That thesis Baselga noted data are immature and likely to Improve.

The most common adverse effects reported in the exemestane and combination groups alone were stomatitis (8% and 1%, respectively), anemia (5% and 1%), dyspnea (4% and 1%), hypoglycemia (4% and < 1%), fatigue (3% and 1%), and pneumonitis (3% and 0%).

"The safety profile was consistent with previous experience everolimus," Dr. Baselga Explained.

In a statement from the manufacturer, Novartis Oncology President Hervé Hoppenot said: "Everolimus is the first drug to show significant efficacy When combined with hormone therapy in ER-positive and HER2-negative breast cancer, where there continues to be a critical unmet need. "

"The magnitude of benefit seen in patiënten thesis, despite resistance to previous Their Hormonal therapies, everolimus Represents That shows a potential important new treatment approach," he added.

This trial was funded BOLERO-2 by Novartis. Dr. Baselga reports acting as a consultant for many pharmaceutical companies, include Novartis, Roche, Merck SA, and Bayer.

2011 European Multidisciplinary Cancer Congress (EMCC): Abstract 9LBA. Presented September 26, 2011.